Poze (pioglitazone hydrochloride) is an oral antidiabetic agent that is used in the management of type 2 diabetes. It acts primarily by decreasing insulin resistance. It improves sensitivity to insulin in muscle and adipose tissue and inhibits hepatic gluconeogenesis. It reduces circulating insulin levels and improves glycemic control
